CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists

Journal of Molecular Modeling

Volumn 16, Issue 4, 2010, Pages 677-691

  Cichero, Elena ^a   Cesarini, Sara ^a   Mosti, Luisa ^a   Fossa, Paola ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

3D QSAR; Cannabinoid receptor; CB2 agonist; CoMFA; CoMSIA

Indexed keywords

4 OXO 1,4 DIHYDRO 1,5 NAPHTHYRIDINE; 4 OXO 1,4 DIHYDRO 1,6 NAPHTHYRIDINE; 4 OXO 1,4 DIHYDRO 1,8 NAPHTHYRIDINE; 4 OXO 1,4 DIHYDROQUINOLINE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; NAPHTHYRIDINE DERIVATIVE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; QUINOLINE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CHEMICAL STRUCTURE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; CHEMISTRY; DRUG POTENTIATION; HUMAN; METABOLISM; PROTEIN BINDING;

HUMANS; MODELS, MOLECULAR; NAPHTHYRIDINES; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; QUINOLINES; RECEPTOR, CANNABINOID, CB2;

EID: 77954600006     PISSN: 16102940     EISSN: 09485023     Source Type: Journal    
DOI: 10.1007/s00894-009-0580-4     Document Type: Article

References (29)

1. Palmer SL, Thakur GA, Makriyannis A (2002) Cannabinergic ligands. Chem Phys Lipids 121:3-19.
2. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
3. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
4. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI (2003) Cannabinoids and neuropathic pain. Mini Rev Med Chem 3:765- 772.
5. Calignano A, La Rana G, Piomelli D (2001) Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol 419:191-198.
6. Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR (2000) Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem 75:2434-2444.
7. Hájos N, Ledent C, Freund TF (2001) Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4.
8. Whiteside GT, Lee GP, Valenzano KJ (2007) The role of the cannabinoid CB2 receptor in pain transmission and therapeutic potential of small molecule CB2 receptor agonists. Curr Med Chem 14:917-936.
9. Ashton JC (2007) Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007(8):373-384.
10. Giblin GM, O'Shaughnessy CT, Naylor A, Mitchell WL, Eatherton AJ, Slingsby BP, Rawlings DA, Goldsmith P, Brown AJ, Haslam CP, Clayton NM, Wilson AW, Chessell IP, Wittington AR, Green R (2007) Discovery of 2-[(2, 4- dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]- 4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain. J Med Chem 50:2597-2600.
11. Guindon J, Hohmann AG (2008) Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153:319-334.
12. Khanolkar AD, Lu D, Ibrahim M, Duclos RI, Thakur GA, Malan TP, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papahatjis DP, Makriyannis A (2007) Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem 50:6493-6500.
13. Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M (2007) Trends Pharmacol Sci 28:39-45.
14. Maccarrone M, Battista N, Centonze D (2007) The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases. Prog Neurobiol 81:349-379.
15. Centonze D, Finazzi-Agro A, Bernardi G, Maccarrone M (2007) The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol Sci 28:180-187.
16. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M (2002) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100:627-634.
17. Velasco G, Galve-Roperh I, Sánchez C, Blázquez C, Guzmán M (2004) Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacol 47:315-323.
18. Pertwee RG (2002) Cannabinoids and multiple sclerosis. Pharmocol Therapeut 95:165-174.
19. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A (2006) Peripheral cannabinoid receptor, CB2, regulates bone mass. Bab I. Proc Nat Acad Sci USA 103:696-701.
20. Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774-779.
21. Lu ZL, Saldanha JW, Hulme EC (2002) Seven-transmembrane receptors: crystals clarify. Trends Pharmacol 23:140-146.
22. Pasquini S, Botta L, Semeraro T, Mugnaini C, Ligresti A, Palazzo E, Maione S, Di Marzo V, Corelli F (2008) Investigations on the 4-Quinolone-3-carboxylic acid motif. 2. Synthesis and structure activity relationship of potent and selective cannabinoid-2 receptor agonist endowed with analgesic activity in vivo. J Med Chem 51:5075-5084.
23. Manera C, Cascio MG, Benetti V, Allarà M, Tuccinardi T, Martinelli A, Saccomanni G, Vivoli E, Ghelardini C, Di Marzo V, Ferrarini PL (2007) New 1, 8-naphthyridine and quinoline derivatives as CB2 selective agonist. Bioorg Med Chem Lett 17:6505-6510.
24. Stern E, Muccioli GG, Bosier B, Hamtiaux L, Millet R, Poupaert JH, Hénichart JP, Depreux P, Goossens JF, Lambert DM (2007) Pharmacomodulations around the 4-oxo-1, 4-dihydroquinoline-3- carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality. J Med Chem 50:5471-5484.
25. Stern E, Muccioli GG, Millet R, Goossens JF, Farce A, Cravatte P, Poupaert JH, Lambert DM, Depreux P, Hénichart JP (2006) Novel 4-oxo-1, 4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. J Med Chem 49:70-79.
26. MOE: chemical Computing Group Inc . Montreal. H3A 2R7 Canada. http://www.chemcomp.com.
27. Cramer RD III, Patterson DE, Bunce JD (1989) Recent advances in comparative molecular field analysis (CoMFA). Prog Clin Biol Res 291:161-165.
28. Klebe G, Abraham U, Mietzner T (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130-4146.
29. Sybyl 7 0. Tripos Inc 1699 South Hanley Road. St Louis, MO, .